Biontech Se

This study tests a new mRNA vaccine (BNT166a) to see if it is safe and triggers a strong immune response against mpox (formerly monkeypox). About 310 healthy adults in African countries will receive either the vaccine or a placebo. The trial includes people who have never been ex…

This study tests a new drug (BNT314) designed to help the immune system attack cancer, combined with another immune-boosting drug (BNT327) and chemotherapy. It is for people with advanced colorectal cancer that did not respond well to initial treatment or, in one part, for those …

This early-stage study tests a new drug, BNT317, in about 39 people with advanced solid tumors who have no other treatment options. The main goal is to check safety and find the best dose. Researchers will also look at how the drug works in the body and if it can shrink tumors.

This study tests two experimental drugs, BNT324 and BNT327, together in people with advanced lung cancer that has spread or come back. The goal is to see if the combination can shrink tumors and control the disease. About 594 adults with small cell or non-small cell lung cancer w…

This study tests two experimental drugs, BNT326 and BNT327, together in people with advanced non-small cell lung cancer that has spread or come back. The goal is to see if the combination can shrink tumors and control the disease. About 420 adults will take part, and the study wi…

This study is for adults with advanced solid tumors who have run out of standard treatments. It tests a new drug called BNT3212, either alone or with another drug (pumitamig), to see if it is safe and can shrink tumors. The trial is in early phases (1 and 2) and will enroll about…

This study tests a new drug called BNT323 (also known as DB-1303) against standard chemotherapy in 480 adults whose endometrial cancer has come back after previous treatment. The cancer must have a certain protein (HER2) on its surface. The main goals are to see if BNT323 slows c…

This study tests a new drug called pumitamig combined with standard chemotherapy for people with advanced non-small cell lung cancer whose disease worsened after initial treatment. About 60 participants will receive the combination to see if it is safe and helps shrink tumors. Th…

This study tests whether adding the experimental drug BNT327 to standard chemotherapy helps people with a tough-to-treat type of breast cancer (triple-negative) that has spread and cannot be removed by surgery. About 558 participants will be randomly assigned to receive either BN…

This early-stage study tests a lab-made antibody called BNT351 in up to 61 adults, both with and without HIV. The main goals are to check safety, how long the antibody stays in the body, and whether it can lower HIV levels in people with the virus. This is not a cure—participants…

This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors and control the disease. About 380 adults with specific HER2-positive, HER2-low…

This study tests a new drug called BNT329 in people with advanced solid tumors that have a specific marker (CA19-9). The main goals are to check safety and find the best dose. About 245 participants will take part. The drug is designed to attack cancer cells while limiting harm t…

This study tests an experimental drug called pumitamig, alone or with other medicines, in adults whose glioblastoma (a fast-growing brain cancer) has returned after standard treatment. The goal is to see if these treatments can shrink tumors and control the disease. About 75 part…

This study tests an experimental drug called BNT326 in people with advanced solid tumors that have spread or come back after other treatments. The goal is to find the best dose and see if it is safe and effective, both alone and when combined with other cancer immunotherapies. Ab…

This study tests a new drug called BNT327 combined with chemotherapy and other agents in people who have not yet been treated for advanced non-small cell lung cancer. The trial will include about 1,260 participants across multiple sites worldwide. The goal is to see if the combin…

This study tests whether adding an experimental vaccine (BNT113) to a standard immunotherapy (pembrolizumab) works better than the immunotherapy alone for people with advanced head and neck cancer caused by HPV. About 350 adults with incurable, recurrent, or metastatic cancer wil…

This study tests if a new drug called BNT324 works better than standard chemotherapy (docetaxel plus steroids) for men with a type of advanced prostate cancer that no longer responds to hormone therapy. About 736 men who have already tried one hormone treatment but not chemothera…

This study tests a new experimental drug, BNT116, for people with advanced non-small cell lung cancer. The goal is to find safe doses when given alone or with other cancer treatments. About 320 participants will take part in this early-phase trial.

This study is the first time the experimental drug BNT3214 is being tested in people. It aims to find a safe dose and see if it can shrink tumors in adults with advanced solid cancers that have not responded to other treatments. About 533 participants will take part across multip…

This study tests whether a new drug called BNT327, combined with standard chemotherapy, helps people with advanced small-cell lung cancer live longer compared to another approved drug combo. About 621 adults who have not yet been treated for this cancer will take part. The goal i…

This study tests a new drug called BNT327 combined with chemotherapy in people with metastatic pancreatic cancer that has not been treated before. The goal is to see if the combination can shrink tumors and control the disease. About 105 adults will take part, and the study is cu…